SG11202006526YA - Antisense oligonucleotides targeting alpha-synuclein and uses thereof - Google Patents

Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Info

Publication number
SG11202006526YA
SG11202006526YA SG11202006526YA SG11202006526YA SG11202006526YA SG 11202006526Y A SG11202006526Y A SG 11202006526YA SG 11202006526Y A SG11202006526Y A SG 11202006526YA SG 11202006526Y A SG11202006526Y A SG 11202006526YA SG 11202006526Y A SG11202006526Y A SG 11202006526YA
Authority
SG
Singapore
Prior art keywords
synuclein
antisense oligonucleotides
oligonucleotides targeting
targeting alpha
alpha
Prior art date
Application number
SG11202006526YA
Other languages
English (en)
Inventor
Richard Olson
Angela Cacace
Jere Meredith
Nino Devidze
James Loy
Carl Baldick
Annapurna Pendri
Ivar Mcdonald
Peter Hagedorn
Marianne Jensen
Original Assignee
Bristol Myers Squibb Co
Roche Innovation Ct Copenhagen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Roche Innovation Ct Copenhagen As filed Critical Bristol Myers Squibb Co
Publication of SG11202006526YA publication Critical patent/SG11202006526YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202006526YA 2018-01-12 2019-01-11 Antisense oligonucleotides targeting alpha-synuclein and uses thereof SG11202006526YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862616937P 2018-01-12 2018-01-12
PCT/US2019/013249 WO2019140231A1 (en) 2018-01-12 2019-01-11 Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Publications (1)

Publication Number Publication Date
SG11202006526YA true SG11202006526YA (en) 2020-08-28

Family

ID=65269095

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006526YA SG11202006526YA (en) 2018-01-12 2019-01-11 Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Country Status (15)

Country Link
US (3) US11447775B2 (es)
EP (1) EP3737387A1 (es)
JP (2) JP7455746B2 (es)
KR (1) KR20200140793A (es)
CN (1) CN111836624A (es)
AU (1) AU2019208006A1 (es)
BR (1) BR112020013994A2 (es)
CA (1) CA3088112A1 (es)
CO (1) CO2020008425A2 (es)
EA (1) EA202091695A1 (es)
IL (1) IL275902A (es)
MX (1) MX2020007433A (es)
PE (1) PE20201501A1 (es)
SG (1) SG11202006526YA (es)
WO (1) WO2019140231A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI809004B (zh) 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
WO2019140231A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN111819283A (zh) * 2018-01-12 2020-10-23 百时美施贵宝公司 靶向α-突触核蛋白的反义寡核苷酸及其用途
JP7317029B2 (ja) 2018-02-12 2023-07-28 アイオーニス ファーマシューティカルズ， インコーポレーテッド 修飾化合物及びその使用

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5102785A (en) 1987-09-28 1992-04-07 E. I. Du Pont De Nemours And Company Method of gene mapping
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
JPH0874B2 (ja) 1990-07-27 1996-01-10 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
EP1331011A3 (en) 1991-10-24 2003-12-17 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
EP1256589A3 (en) 1991-11-26 2003-09-17 Isis Pharmaceuticals, Inc. Oligomers containing modified pyrimidines
CA2151585A1 (en) 1992-12-14 1994-06-23 Benjamin Weiss Administration of oligonucleotides antisense to dopamine receptor mrna for diagnosis and treatment of neurological pathologies
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5981279A (en) 1995-11-09 1999-11-09 Allegheny University Of The Health Sciences Compositions and methods to regulate calmodulin gene expression, and uses thereof for influencing cell growth and differentiation
AU2582197A (en) 1996-03-15 1997-10-01 Start Technology Partnership Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US5932557A (en) 1997-08-12 1999-08-03 Mustafa; S. Jamal Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments
IL135000A0 (en) 1997-09-12 2001-05-20 Exiqon As Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6833361B2 (en) 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
BR9911596A (pt) 1998-05-26 2001-10-02 Icn Pharmaceuticals Nucleosìdeos tendo porção açúcar bicìclico
WO1999061066A2 (en) 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
CA2333857A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
WO2000025798A1 (en) 1998-11-05 2000-05-11 Thomas Jefferson University Treatment of parkinson's disease with oligonucleotides
US20040226056A1 (en) 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
EP1140973A4 (en) 1998-12-22 2002-10-30 Myriad Genetics Inc PROTEIN-PROTEIN INTERACTIONS IN NEURODEGENERATIVE DISORDERS
TR200604211T1 (tr) 1999-02-12 2007-02-21 Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited Yeni nükleosid ve oligonükleotid analoglarıYeni nükleosid ve oligonükleotid analogları
AU5081200A (en) 1999-05-04 2000-11-17 Aventis Pharma S.A. Use of inducible no-synthase antisense oligonucleotides for preventing and treating cerebral ischemia
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
WO2001005963A2 (en) 1999-07-15 2001-01-25 Mcgill University ANTISENSE OLIGONUCLEOTIDES FOR METABOTROPIC GLUTAMATE RECEPTOR TYPE 1 (mGluR1)
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
WO2001077384A2 (de) 2000-04-07 2001-10-18 Epigenomics Ag DETEKTION VON SNPs UND CYTOSIN-METHYLIERUNGEN
US20030032791A1 (en) 2000-06-26 2003-02-13 Alan Robertson Scott Novel melanocortin-4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate
US6277640B1 (en) 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
US20030060438A1 (en) 2000-08-18 2003-03-27 Henry James L. Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof
US20020119155A1 (en) 2000-10-17 2002-08-29 Myriad Genetics, Inc. Protein-protein interactions in neurodegenerative diseases
US6653102B2 (en) 2000-10-17 2003-11-25 Myriad Genetics, Inc. Nucleic acid encoding a phosphatase 2C that interacts with Fe 65
US20020151506A1 (en) 2000-12-29 2002-10-17 Castillo Gerardo M. Catechins for the treatment of fibrillogenesis in Alzheimer's disease, Parkinson's disease, systemic AA amyloidosis, and other amyloid disorders
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
US6455308B1 (en) 2001-08-01 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of serum amyloid A4 expression
US20050014689A1 (en) 2001-10-02 2005-01-20 Eiji Sugaru Remedies for life style-related diseases or cibophobia and method of screening the same
US20030143738A1 (en) 2001-11-08 2003-07-31 Hiroki Yokota Compositions and methods for treating ischemic stroke
EP1468694A1 (en) 2001-12-27 2004-10-20 Sumitomo Pharmaceuticals Company, Limited Remedies for anorexia or lifestyle-related diseases and method of screening the same
SI1511710T1 (sl) 2002-05-31 2014-04-30 Proteotech, Inc. Spojine, sestavki in postopki za zdravljenje amiloidnih bolezni in sinukleinopatij, kot je Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsova bolezen
US20070276034A1 (en) 2002-05-31 2007-11-29 Luke Esposito Compounds, compositions and methods for the treatment of synucleinopathies
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
US7696345B2 (en) 2002-11-05 2010-04-13 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
DK3222722T3 (da) 2002-11-18 2019-06-17 Roche Innovation Ct Copenhagen As Antisense-design
CA2515368A1 (en) 2003-02-13 2004-08-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
CA2522497A1 (en) 2003-04-16 2004-11-04 Whitehead Institute For Biomedical Research Yeast ectopically expressing abnormally processed proteins and uses therefor
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
US20050032695A1 (en) 2003-05-30 2005-02-10 Aventis Pharma Deutschland Gmbh Method for alleviating pain using protein associated with MYC and related compounds, and assays for identifying such compounds
EP1481680A1 (en) 2003-05-30 2004-12-01 Aventis Pharma Deutschland GmbH Use of S1P
EP1481685A1 (en) 2003-05-30 2004-12-01 Aventis Pharma Deutschland GmbH Use of PAM
AU2004255557B2 (en) 2003-06-09 2010-06-10 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
US7595306B2 (en) 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
WO2005027962A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
RU2385933C2 (ru) 2004-02-09 2010-04-10 Реженьон Гмбх Ингибиторы передачи сигнала трансформирующих факторов роста (tgf-r) для лечения расстройств цнс
EP2540734B1 (en) 2004-04-05 2016-03-30 Alnylam Pharmaceuticals, Inc. Process and reagents for oligonucleotide synthesis and purification
AU2005286738A1 (en) 2004-09-17 2006-03-30 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
CA2580189C (en) 2004-09-29 2013-05-21 Children's Memorial Hospital Sirna-mediated gene silencing of alpha synuclein
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
US20080003570A1 (en) 2004-12-22 2008-01-03 The General Hospital Corporation Translation enhancer elements of genes encoding human Tau protein and human alpha-synuclein protein
US7776538B2 (en) 2005-03-03 2010-08-17 National University Corporation Nagoya University Method for diagnosing methamphetamine dependence
WO2006093034A1 (ja) 2005-03-03 2006-09-08 National University Corporation Nagoya University 精神障害関連遺伝子及びその利用
US20080206253A1 (en) 2005-03-14 2008-08-28 Xiao-Ying Hua Method For Preventing or Treating Pain in a Mammal
EP3308788B1 (en) 2005-06-23 2018-10-24 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007030581A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
WO2007030580A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
US20100130425A1 (en) 2005-09-09 2010-05-27 Oregon Health & Science University Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
CA2622583A1 (en) 2005-09-15 2007-03-22 Henrik Frydenlund Hansen Rna antagonist compounds for the inhibition of apo-b100 expression
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
JP2009521470A (ja) 2005-12-23 2009-06-04 リンク メディシン コーポレイション シヌクレイン障害の治療
JP5425474B2 (ja) 2006-01-26 2014-02-26 アイシス ファーマシューティカルズ， インコーポレーテッド ハンチンチン対する、組成物及びその使用
PL1984381T3 (pl) 2006-01-27 2011-03-31 Isis Pharmaceuticals Inc Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
EP2019692B1 (en) 2006-05-05 2014-06-04 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of gccr
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
JP5441688B2 (ja) 2006-05-11 2014-03-12 アイシス ファーマシューティカルズ， インコーポレーテッド ５’修飾二環式核酸類似体
GB0610183D0 (en) 2006-05-23 2006-06-28 Isis Innovation Treatment of neurodegenerative diseases
WO2008003943A2 (en) 2006-07-03 2008-01-10 Zapaloid Limited Inhibition of alpha-synuclein aggregation
KR20080036902A (ko) 2006-10-24 2008-04-29 재단법인서울대학교산학협력재단 아밀로이드 형성 펩타이드 또는 단백질의 가용성 회합체에선택적으로 작용하는 절단제
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
CA2678963C (en) 2007-02-23 2018-05-01 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
EP2176280B2 (en) 2007-07-05 2015-06-24 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
GB0715809D0 (en) * 2007-08-14 2007-09-26 Univ Leuven Kath Alpha synuclein toxicity
WO2009023855A2 (en) 2007-08-15 2009-02-19 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US8012116B2 (en) 2007-08-17 2011-09-06 Marc Ronald Del Bigio Device to reduce brain edema by surface dialysis and cooling
EP2623598B1 (en) 2007-10-04 2018-08-01 Roche Innovation Center Copenhagen A/S Micromirs
US20090123575A1 (en) 2007-11-12 2009-05-14 Thomas Lake Blended Compositions for Treatment of Alzheimer's Disease and Other Amyloidoses
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2009079399A2 (en) 2007-12-14 2009-06-25 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
DK2285819T3 (da) 2008-04-04 2013-12-02 Isis Pharmaceuticals Inc Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
US20100056622A1 (en) 2008-08-27 2010-03-04 Lauterbach Edward C Methods of Using Ramelteon to Treat Patients Suffering from a Variety of Neurodegenerative Diseases
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
ES2544569T3 (es) * 2008-12-19 2015-09-01 Biogen International Neuroscience Gmbh Autoanticuerpos humanos anti alfa-sinucleina
BRPI1015472A2 (pt) 2009-04-09 2015-11-24 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central
KR20210057223A (ko) 2009-06-17 2021-05-20 바이오젠 엠에이 인코포레이티드 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2011048125A1 (en) 2009-10-20 2011-04-28 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
EP3231446A1 (en) 2010-04-19 2017-10-18 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US9290759B2 (en) 2010-08-25 2016-03-22 The Trustees Of Columbia University In The City Of New York Optimized miRNA constructs
AU2011329777B2 (en) 2010-11-17 2016-06-09 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
CN104136451A (zh) 2011-09-07 2014-11-05 玛瑞纳生物技术有限公司 具有构象限制的单体的核酸化合物的合成和用途
US20140235696A1 (en) 2011-09-28 2014-08-21 Royal College Of Surgeons In Ireland Inhibition of microrna-134 for the treatment of seizure-related disorders and neurologic injuries
WO2013154798A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
US20140155816A1 (en) 2012-10-09 2014-06-05 Eu Sol Biotech Co., Ltd. Method for treating brain injury or stroke
WO2014059341A2 (en) 2012-10-12 2014-04-17 Isis Pharmaceuticals, Inc. Antisense compounds and uses thereof
AU2013346767B2 (en) 2012-11-15 2019-04-11 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
EP2951191B1 (en) 2013-01-31 2018-10-17 Ionis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified coupling protocols
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
AU2014259755B2 (en) 2013-05-01 2018-08-30 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
CN105358692B (zh) 2013-06-27 2020-08-21 罗氏创新中心哥本哈根有限公司 靶向pcsk9的反义寡聚体和缀合物
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
US9925277B2 (en) 2013-09-13 2018-03-27 Modernatx, Inc. Polynucleotide compositions containing amino acids
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JP6679476B2 (ja) 2013-10-11 2020-04-15 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｃ９ｏｒｆ７２発現を調節するための組成物
AU2014337156A1 (en) 2013-10-18 2016-05-12 Modernatx, Inc. Compositions and methods for tolerizing cellular systems
EP3076994A4 (en) 2013-12-06 2017-06-07 Modernatx, Inc. Targeted adaptive vaccines
US20170002060A1 (en) 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
RU2746406C2 (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
WO2016022914A1 (en) 2014-08-08 2016-02-11 Moderna Therapeutics, Inc. Compositions and methods for the treatment of ophthalmic diseases and conditions
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
JP2017536366A (ja) 2014-11-19 2017-12-07 ロシュ イノベーション センター コペンハーゲン エーエス Ｌｎａキラルホスホロチオエート
CN107709560A (zh) 2015-04-15 2018-02-16 哈德森医学研究所 治疗方法
KR102104163B1 (ko) 2015-04-16 2020-04-23 아이오니스 파마수티컬즈, 인코포레이티드 C9orf72 발현을 조절하기 위한 조성물
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
WO2017053995A1 (en) 2015-09-25 2017-03-30 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
JP2018528783A (ja) 2015-09-25 2018-10-04 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． コンジュゲートアンチセンス化合物及びその使用
EP3415524A4 (en) 2016-01-07 2019-09-04 Osaka University INHIBITOR OF EXPRESSION OF α-SYNUCLEIN
EP3448875A4 (en) 2016-04-29 2020-04-08 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
AR109750A1 (es) 2016-09-29 2019-01-23 Ionis Pharmaceuticals Inc Compuestos y métodos para reducir la expresión de tau
JPWO2019009299A1 (ja) 2017-07-05 2020-05-07 国立大学法人大阪大学 α−シヌクレイン発現抑制するＥＮＡアンチセンスオリゴヌクレオチド
WO2019009298A1 (ja) 2017-07-05 2019-01-10 国立大学法人大阪大学 α－シヌクレイン発現抑制剤
TWI809004B (zh) 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
CR20200301A (es) 2018-01-12 2020-10-26 Roche Innovation Ct Copenhagen As Oligonucleótidos antisentido para alfa-sinucleína y usos de los mismos
WO2019140231A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN111819283A (zh) 2018-01-12 2020-10-23 百时美施贵宝公司 靶向α-突触核蛋白的反义寡核苷酸及其用途
WO2019195519A1 (en) 2018-04-06 2019-10-10 Ionis Pharmaceuticals, Inc. Methods of modulating antisense activity
JP2021522800A (ja) 2018-05-09 2021-09-02 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ａｔｘｎ３発現を低減するための化合物及び方法
US11833168B2 (en) 2018-06-14 2023-12-05 Ionis Pharmaceuticals, Inc. Compounds and methods for increasing STMN2 expression
MX2020013653A (es) 2018-06-27 2021-03-02 Ionis Pharmaceuticals Inc Compuestos y metodos para la reduccion de la expresion de lrrk2.
EP3826645A4 (en) 2018-07-25 2023-05-17 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR REDUCING ATXN2 EXPRESSION
US20220280545A1 (en) 2018-09-10 2022-09-08 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating cln3 expression
US20220031731A1 (en) 2018-09-20 2022-02-03 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of lmna expression
MX2021005886A (es) 2018-11-21 2021-06-23 Ionis Pharmaceuticals Inc Compuestos y metodos para reducir la expresion de priones.
JP2022515140A (ja) 2018-12-21 2022-02-17 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｐｍｐ２２の発現を低減するための化合物及び方法
UY38562A (es) 2019-01-29 2020-08-31 Ionis Pharmaceuticals Inc Compuestos y métodos para reducir la expresión de app

Also Published As

Publication number Publication date
JP2024037914A (ja) 2024-03-19
CN111836624A (zh) 2020-10-27
CO2020008425A2 (es) 2020-08-21
MX2020007433A (es) 2020-09-14
US11359197B2 (en) 2022-06-14
CA3088112A1 (en) 2019-07-18
EP3737387A1 (en) 2020-11-18
AU2019208006A1 (en) 2020-07-23
KR20200140793A (ko) 2020-12-16
BR112020013994A2 (pt) 2020-12-08
US20210180065A1 (en) 2021-06-17
IL275902A (en) 2020-08-31
US11447775B2 (en) 2022-09-20
JP2021510512A (ja) 2021-04-30
JP7455746B2 (ja) 2024-03-26
WO2019140231A1 (en) 2019-07-18
PE20201501A1 (es) 2020-12-29
EA202091695A1 (ru) 2021-02-08
US20200354720A1 (en) 2020-11-12
US20230193260A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
IL276549A (en) CAMK2D antisense oligonucleotides and their uses
IL275950A (en) Antisense alpha-synuclein oligonucleotides and their use
SG11202001208XA (en) Rna targeting methods and compositions
IL275903A (en) Antisense oligonucleotides directed against alpha-synculin and their uses
IL280536A (en) Muscle oriented clasps and their uses
IL268422A (en) Targeted oligonucleotides
IL275902A (en) Antisense oligonucleotides directed against alpha-synculin and their uses
IL268894A (en) Medical RNA
GB201711809D0 (en) Antisense oligonucleotide
EP3353306A4 (en) ANTISENSE CONJUGATED COMPOUNDS AND THEIR USE
EP3353305A4 (en) Conjugated antisense compounds and their use
IL269714A (en) Oligonucleotide probes and their uses
SG11202101288TA (en) Modified oligonucleotides targeting snps
EP3704269C0 (en) OLIGONUCLEOTIDE CONSTRUCTS AND USES THEREOF
IL284447A (en) Dux4 rna silencing using rna targeting crispr-cas13b
IL274115A (en) The rust resistance gene (WTK1 (Yr15) and its use
IL268687A (en) Antibody targeting IL-13RA2 and its uses
IL280581A (en) RNAi variant against alpha-synuclein
EP3724206A4 (en) CONJUGATE ANTISEN COMPOUNDS AND THEIR USE
SG10201913477UA (en) G-quadruplex-containing antisense oligonucleotides
IL271039A (en) Antisense oligonucleotides regulate htra1 expression
SG10201609048RA (en) Antisense oligonucleotides
SG10202008771WA (en) Combination therapy with liposomal antisense oligonucleotides
IL286826A (en) angptl2 oligonucleotides and their use
EP4069844A4 (en) ANTI-SLC6A1 OLIGONUCLEOTIDES AND RELATED METHODS